Recombinant Rat PD-L1/B7-H1 Fc Chimera Protein, CF

When Recombinant Rat PD-1 Fc Chimera (Catalog # 9814‑PD) is coated at 1 µg/mL, Recombinant Rat PD-L1/B7-H1 Fc Chimera(Catalog # 9835‑B7) binds with an ED50 of 0.09‑0.54 µg/mL.

• Reactivity: Rt
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Rat PD-L1/B7-H1 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. Immobilized Recombinant Rat PD-1 Fc Chimera (Catalog # 9814-PD) at 1 µg/mL (100 µL/well) can bind Recombinant Rat PD‑L1/B7-H1 Fc Chimera with an ED₅₀ of 0.09-0.54 μg/mL.
• Source: Mouse myeloma cell line, NS0-derived rat PD-L1/B7-H1 protein
  

  Rat B7-H1 (Phe19-Thr238) Accession # NP_001178883	IEGRMDP	Mouse IgG2a (Glu98-Lys330)
  N-terminus		C-terminus

• Accession #: NP_001178883
• N-terminal Sequence: Phe19
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 52 kDa .
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 74-84 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage:
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Rat PD-L1/B7-H1 Fc Chimera Protein, CF

• Avelumab
• B7-H
• B7H1
• B7-H1
• B7H1PDCD1L1
• CD274 antigenMGC142294
• CD274 molecule
• CD274
• PDCD1L1
• PDCD1LG1
• PDCD1LG1MGC142296
• PDL1
• PD-L1
• PD-L1B7 homolog 1
• PDL1PDCD1 ligand 1
• programmed cell death 1 ligand 1
• Programmed death ligand 1

Background

B7-H1, also known as PD-L1 and CD274, is an approximately 52 kDa transmembrane glycoprotein in the B7 family of immune-regulatory molecules (1). Mature rat B7-H1 consists of a 220 amino acid (aa) extracellular domain (ECD) with two Ig-like domains, a 21 aa transmembrane segment, and a 30 aa cytoplasmic domain (2). Within the ECD, rat B7-H1 shares 74% and 86% aa sequence identity with human and mouse, respectively. B7-H1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells (3-6), keratinocytes (7, 8), enothelial and intestinal epithelial cells (8-10), as well as a variety of carcinomas and melanoma (10, 11). B7-H1 binds to T cell B7-1/CD80 and PD-1 (6, 7, 11-14). It suppresses T cell activation and proliferation (4, 7, 13, 15) and induces the apoptosis of activated T cells (10). It plays a role in the development of immune tolerance by promoting T cell anergy (6, 13) and enhancing regulatory T cell development (15). B7-H1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells (4, 9) and inhibits the development of Th17 cells (15). In cancer, B7-H1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells (5, 8, 11, 14).

1. Ceeraz, S. et al. (2013) Trends Immunol. 34:556.
2. Dong, H. et al. (1999) Nat. Med. 5:1365.
3. Tamura, H. et al. (2001) Blood 97:1809.
4. Chen, L. et al. (2007) J. Immunol. 178:6634.
5. Kuang, D.-M. et al. (2014) J. Clin. Invest. 124:4657.
6. Tsushima, F. et al. (2007) Blood 110:180.
7. Mazanet, M.M. and C.C.W. Hughes (2002) J. Immunol. 169:3581.
8. Cao, Y. et al. (2010) Cancer Res. 71:1235.
9. Scandiuzzi, L. et al. (2014) Cell Rep. 6:625.
10. Dong, H. et al. (2002) Nat. Med. 8:793.
11. Azuma, T. et al. (2008) Blood 111:3635.
12. Butte, M.J. et al. (2008) Mol. Immunol. 45:3567.
13. Park, J.-J. et al. (2010) Blood 116:1291.
14. Ritprajak, P. et al. (2010) J. Immunol. 184:4918.
15. Herold, M. et al. (2015) J. Immunol. 195:3584.

Bioinformatics

• Uniprot:
  • NP_001178883()